Online inquiry

IVTScrip™ mRNA-Human ARHGEF12, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK26809MR)

This product GTTS-WK26809MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ARHGEF12 protein. This product can be used in Regulatory T (Treg) cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Human
RefSeq NM_001198665.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 23365
UniProt ID Q9NZN5
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ARHGEF12, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK26809MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK18737MR IVTScrip™ mRNA-Human alpha-SMA, (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA alpha-SMA
GTTS-WK7754MR IVTScrip™ mRNA-Human ADIPOR2, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ADIPOR2
GTTS-WK27983MR IVTScrip™ mRNA-Human ARHGAP15, (Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ARHGAP15
GTTS-WK19123MR IVTScrip™ mRNA-Human ANKRD37, (Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ANKRD37
GTTS-WK16694MR IVTScrip™ mRNA-Human ANKMY1, (Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ANKMY1
GTTS-WK8931MR IVTScrip™ mRNA-Human ADGB, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ADGB
GTTS-WK8669MR IVTScrip™ mRNA-Human ADRBK1, (Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ADRBK1
GTTS-WK11589MR IVTScrip™ mRNA-Human ADAM12, (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ADAM12
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW